Loading patent…
AssigneeThe Population Council, Inc.
InventorsRegine Sitruk-Ware, Michael Maria Helmut Schumacher, Roberta Brinton, Martine El-Etr, Abdelmouman Ghoumari, Rachida Guennoun
Estimating the term…
Methods for treating neurodegeneration and/or myelination in patients are disclosed comprising treating the patient with a progestin compound which exerts binding to progesterone receptors and elicits progesterone-receptor-induced biological responses without interacting with the androgen receptor and without inducing androgen or glucocorticoid biological responses at a dosage sufficient to prevent or reduce neurodegeneration. The progestin compound preferably comprises 16-methylene-17α-acetoxy-19-norpregn-4-ene-3,20-dione, and the methods include combining the progestin compound with an estrogen compound to provide both contraception and treatment for myelin repair and neurodegeneration.
A method for treating neurodegeneration in a patient comprising treating said patient with a pharmaceutically effective dosage of a progestin compound which exerts binding to progesterone receptors and elicits progesterone-receptor-induced biological responses without interacting with the androgen receptor and without inducing androgen or glucocorticoid biological responses, said pharmaceutically effective dosage being 5 mg/day or lower, whereby neurodegeneration is prevented or reduced.
The method of 3 wherein the dosage of said estradiol comprises from about 10 to 150 μg/day.
A method for treating neurodegeneration in post-menopausal women comprising treating said post-menopausal women with a pharmaceutically effective dosage of a progestin compound which exerts binding to progesterone receptors and elicits progesterone-receptor-induced biological responses without interacting with the androgen receptor and without inducing androgenic or glucocordicoid biological responses at a dosage sufficient to prevent or reduce neurodegeneration in said post-menopausal women, and simultaneously providing a predetermined dosage of natural estradiol.
A method for treating neurodegeneration exhibited in a condition selected from the group consisting of Multiple Sclerosis, Alzheimer's Disease, and Parkinson's Disease in a patient comprising treating said patient with a pharmaceutically effective dosage of a progestin compound which exerts binding to progesterone receptors and elicits progesterone-receptor-induced biological responses without interacting with the androgen receptor and without inducing androgenic or glucocorticoid biological responses at a dosage sufficient to prevent or reduce relapses of said conditions.
Dependencies are inferred from the claim text.